Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

This was the stock's second consecutive day of losses.

Humana Inc. closed 43.21% below its 52-week high of $406.46, which the company reached on July 18th.

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

On June 3, Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE: HUM) and a $313 price ...

A month has gone by since the last earnings report for Humana (HUM). Shares have lost about 10.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Humana said it is reaffirming its prior 2025 EPS guidance. The health insurer sees $14.68 in diluted EPS or $16.25 in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...